Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

Novartis looks to squelch neuro worries over its would-be cardio blockbuster

Novartis, at work on a cardio drug widely expected to bring in billions of dollars once approved, is working to tamp down concerns that the oral treatment could increase the risk of Alzheimer's disease, adding measures of brain function to an ongoing trial.

Chiasma hauls in $70M to write its post-Roche future

Israeli-American biotech Chiasma has raised $70 million in Series E cash, moving on from an aborted collaboration with Roche and rolling toward FDA approval with a treatment for the hormone disorder acromegaly.

Viehbacher wades into the startup world, joining PureTech in his first post-Sanofi move

Months after a bitter exit from the top spot at Sanofi, Christopher Viehbacher is back out in public, joining Boston startup factory PureTech to help steer its portfolio of fledgling companies.

Stealthy Lyric Pharma bags $20M for its gastro drug

South San Francisco's Lyric Pharmaceuticals raised $20.4 million in first-round financing to support its work on a hush-hush gastrointestinal drug.

Hospira and Celltrion hit a speed bump in their biosimilar dash

The FDA wants some more time to review Hospira and partner Celltrion's copy of Johnson & Johnson's blockbuster autoimmune drug Remicade, possibly delaying the drug's march onto the U.S. market.

Actavis wins FDA approval for a new 'superbug' antibiotic

Actavis won the FDA's blessing for a new combination antibiotic treatment targeting drug-resistant infections, setting the stage for a showdown with Merck and its $9.5 billion splash into the field.

Introducing FierceBiotech's new podcast

Welcome to FierceBiotech Radio, a podcast in which we'll chat with industry experts, newsmakers and veterans on issues affecting the business of biopharma. The idea is to replicate the off-the-cuff encounters normally confined to insidery confabs, avoiding the dullness of hyperscripted earnings calls and technical webinars.

Takeda's betting on its pipeline to spur a long-awaited turnaround

Japanese giant Takeda Pharmaceutical is planning to finally return to growth next year, counting on its late-stage medicines to the lead charge.

Hospira and Celltrion storm the EU with biosimilars of J&J's Remicade

Partners Hospira and Celltrion are marching forward with copies of Johnson & Johnson's blockbuster autoimmune drug Remicade, bulldozing into Europe with products expected to disrupt a multibillion-dollar market.

AstraZeneca bets $122.5M on oral autoimmune drugs

AstraZeneca is out to get some more shots on goal in immunology, pairing up with a nascent biotech in hopes of developing oral medicines for psoriasis, arthritis and other diseases.